Ultragenyx Pharmaceutical | RARE - Stock


Ultragenyx Pharmaceutical reported $55M in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
Acadia Pharmaceuticals USD 31.57M 3.1M Mar/2026
Agios Pharmaceuticals USD 35.09M 2.17M Mar/2026
Alnylam Pharmaceuticals USD 200.15M 117.43M Mar/2026
BioCryst Pharmaceuticals USD 5.98M 587K Mar/2026
BioMarin Pharmaceutical USD 1.27B 25.66M Mar/2026
Esperion Therapeutics USD 104.21M 915K Mar/2026
Insmed USD 132.91M 841K Mar/2026
Ionis Pharmaceuticals USD 5.56M 4.49M Mar/2026
Karyopharm Therapeutics USD 4.04M 72K Dec/2025
Kyowa Hakko Kirin JPY 67.44B 5.42B Dec/2025
MacroGenics USD 9.5M 1.59M Mar/2026
Moderna USD 146M 7M Mar/2026
Neurocrine Biosciences USD 64.5M 4.5M Mar/2026
PTC Therapeutics USD 75.57M 4.08M Mar/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Regeneron Pharmaceuticals USD 3.1B 97.2M Mar/2026
Sarepta Therapeutics USD 1B 86.37M Mar/2026
Ultragenyx Pharmaceutical USD 55M 3M Mar/2026
Vertex Pharmaceuticals USD 1.77B 79.9M Mar/2026